Studies addressing rheumatoid arthritis (RA) flares, a potential new drug for psoriatic arthritis, and a novel agent in the treatment of active RA are among the highlights
CORRONA Team Provides Data-Based Tool to Address Rheumatology’s Questions
The Consortium of Rheumatology Researchers of North America (CORRONA) patient registry collects a host of treatment and disease indicators for a variety of rheumatic diseases at every physician visit
Ethical Concerns Influence What Constitutes Clear and Full Disclosure for Physicians
Money received from industry by physicians who can influence medical practice by their research, opinions, or roles in decision-making bodies should be clearly and fully disclosed
Rheumatology Drug Updates: Apremilast, Golimumab, and More
Information on new approvals and medication safety rheumatologists need to know
A Few Acronyms and Indices in OMERACT
HAQ: Health Assessment Questionnaire DAS28: Disease Activity Score DAS: Psoriatic Arthritis: ACR Core Data Set and Disease Activity Score PsARC: Psoriatic Arthritis Response Criteria PSAI: Psoriasis Area and Severity Index SLEDAI: SLE Disease Activity Score BILAG: British Isles Lupus Activity Score SLAM: Systemic Lupus Activity Measure LAI: Lupus Activity Index ECLAM: European Consensus Lupus Activity…
Drug Updates: Lorcaserin, Acetaminophen, and More
information on new approvals and medication safety
Drug Updates: EULAR 2012
Tracking the results of drug safety and efficacy
Patient Fact Sheet: Juvenile Idiopathic Arthritis
Several types of arthritis fall under the JIA heading. This inflammation begins before patients reach the age of 16 years, and may involve one or many joints and cause other symptoms such as fevers, rash, and eye inflammation.
Treatment Patterns and Trends for Spondylarthropathies
Methotrexate is a commonly used disease-modifying antirheumatic drug (DMARD) for treating patients with psoriatic arthritis (PsA). However, is it truly as effective as many think it is? That’s the question raised during the session “Spondylarthropathies: Recent Insights,” which took place at the 2011 ACR/ARHP Annual Scientific Meeting in November.
Drug Updates: Apremilast, Belimumab, and More
Information on new approvals and medication safety